Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Giant Cell Arteritis
Interventions: Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more

Conditions: Autism Spectrum Disorder
Interventions: Sertraline Liquid Placebo, Sertraline; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 72 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Encopresis, ASD
Interventions: Glycerin Suppository, Behavioral strategies; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: JNJ-54416076 (Oral Suspension), JNJ-54416076 (Formulation 1: Direct Compression Tablets), JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-melanoma Skin Cancer
Interventions: Acetaminophen; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions: Oxycodone, Ibuprofen, Acetaminophen; Drug
Lead sponsor: David Chi, MD; Other
Eligibility: 3 Years to 17 Years
Enrollment: 268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Liquid biopsy; Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: NIS793, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms, Non-muscle Invasive Bladder Cancer, Bladder Cancer (BC), Transurethral Resection of Bladdertumors, Transurethral Resection of the Bladder, Non-Muscle Invasive Bladder Carcinoma
Interventions: HISA; Device
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration; Procedure · Genetic · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Value of the Bowel Preparation and Diet Change Versus no Intervention, Preoperative Bowel Regimen
Interventions: No bowel prep, Clear liquid diet and 2 Fleet's enemas; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Wound of Skin, Burns
Interventions: KeraStat® Gel with Morphine application, KeraStat® Gel application; Drug
Lead sponsor: The Metis Foundation; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Facial Injuries, Adipose Tissue
Interventions: Repeat Fat grafting; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Binge Eating Disorder
Interventions: Sodium Oxybate; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Degenerative Disc Disease, Isthmic-lytic Spondylolisthesis, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions: Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion; Combination Product
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis
Interventions: Knee injection, ReNu amniotic allograft, placebo saline, Hyaluronic Acid; Procedure · Other · Device
Lead sponsor: NuTech Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Glomerulosclerosis, Focal
Interventions: Cyclosporin, Mycophenolate mofetil and Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Central Nervous System Lymphoma (PCNSL)
Interventions: Nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Ductus Arteriosus, Patent
Interventions: Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac; Device · Combination Product · Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 7 Days to 32 Days
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions: Biocidin REMOVE, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Kidney Injury
Interventions: Furosemide, Peritoneal Dialysis; Drug · Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 6 Months
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Heart Failure
Interventions: MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin; Biological · Drug
Lead sponsor: Melana Yuzefpolskaya, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Beta-thalassemia, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois

Search by objective public record fields.

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

A Trial of Sertraline in Young Children With Autism Spectrum Disorder

Comprehensive Toileting Program

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Preoperative Acetaminophen and Carbohydrate Loading

Non-opioids for Analgesia After Adenotonsillectomy in Children

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Feasibility of HISA During TURBT for NMIBC

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse

Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers

Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort

Sodium Oxybate in the Treatment of Binge Eating Disorder

Efficacy of Using Solum IV and BMC With GFC in TLIF

An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment